In the near future, you may monitor your health and diagnose illness – all by swallowing a biosensor. Prof. Ben Terry of the University of Nebraska, Lincoln, describes this technology, which may sound like science fiction to many.
AABME is conducting a series of webinars to examine a risk-based, conceptual framework developed by the US Food and Drug Administration (FDA) for use at point-of-care manufacturing facilities. Webinar panels will include speakers from diverse groups, including medical device manufacturers, point-of-care manufacturers, technology developers, and the FDA. The framework includes the following scenarios:
A. Minimal Risk 3DP by a Healthcare Professional
B&C. Device Designed by Manufacturer Using Validated Process
D. Manufacturer Co-Located at Point of Care
E. Healthcare Facility Becomes a Manufacturer
In the tissue engineering industry there is a lot of discussion around the complexities of seeding adherent cells, the best modes for generating vascularized scaffolds, the challenges associated with the packaging and transport of tissue-engineered medical products (TEMPs), and how to get your product to market quickly.
This presentation will provide a brief description of the various forms of VR technology and describe the trajectory of Clinical VR over the last 20 years addressing health and clinical treatment of anxiety disorders, PTSD, pain management, autism, and in the assessment/rehabilitation of stroke, brain injury, and other neurologically-based conditions. We will also discuss advances in Virtual Human technology for clinical training, healthcare coaching, and clinical interviewing.